Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible? | Satellite Symposium
A Talk by Jorge A. Garcia , Vadim Koshkin and Shilpa Gupta
Proudly supported by
About this Talk
Satellite Symposium Agenda:
Expert Talk 1: Front-line Management for Advanced Bladder Cancer: Chemo is No Longer Enough
Jorge A. Garcia
*Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. Expert Talk 2: Ongoing Clinical Trials in Advanced Urothelial Carcinoma and Future Directions
Vadim Koshkin
*Division of Hematology and Oncology, University of California San Francisco Expert Talk 3: Treatment Options for Second-Line Therapy and Beyond in Urothelial Carcinoma
Shilpa Gupta
*Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio Expert Panel Discussion and Questions & Answers
Panelists: Shilpa Gupta, Vadim Koshkin and Jorge A. Garcia
Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, Division of Hematology and Oncology, University of California San Francisco and *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Learning Objectives:
After completing the independent medical educational activity, learners will be able to:
-
Understand and explain relevant and current clinical trials and updates regarding immunotherapy as maintenance therapy in la/mUC patients.
-
Learn and understand which patients should be followed up with immunotherapy maintenance treatment.
Certificate of attendance: The certificates will be given to those attendees who will complete pre & post symposium evaluation quiz.
Conflict of interests: No known conflict of interests
Acknowledgment: This symposium is supported by an educational grant from Pfizer and Merck.